2-Metil-6-(feniletinil)piridin (MPEP) je lek koji se koristi u naučnim istraživanjima. On je bio jedan od prvih selektivnih antagonistametabotropnog glutamatnog receptoramGluR5. Ovo jedinjenje je razvila farmaceutska kompanija Novartis krajem 1990-tih.[4] On proizvodi neuroprotektivne efekte nakon akutne moždane povrede u životinjskim ispitivanjima, mada nije jasno da li su ti rezultati direktna posledica mGluR5 blokade, jer on deluje i kao slab NMDA antagonist,[5][6] i kao pozitivni alosterni modulator mGlu4 receptora,[7] a isto tako postoje dokazi o funkcionalnim interakcijama između mGluR5 i NMDA receptora u pojedinim populacijama neurona.[8] Takođe je pokazano da proizvodi antidepresivne[9][10][11] i anksiolitičke efekte kod životinja,[12][13][14] i da umanjuje dejstvo morfinskog povlačenja,[15] najverovatnije usled direktne interakcije između mGluR5 i μ-opioidnog receptora.[16]
↑Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑Micheli, F (2000). „Methylphenylethynylpyridine (MPEP) Novartis”. Current opinion in investigational drugs (London, England : 2000)1 (3): 355–9. PMID11249719.
↑Movsesyan, VA; O'Leary, DM; Fan, L; Bao, W; Mullins, PG; Knoblach, SM; Faden, AI (2001). „MGluR5 antagonists 2-methyl-6-(phenylethynyl)-pyridine and (E)-2-methyl-6-(2-phenylethenyl)-pyridine reduce traumatic neuronal injury in vitro and in vivo by antagonizing N-methyl-D-aspartate receptors”. The Journal of Pharmacology and Experimental Therapeutics296 (1): 41–7. PMID11123360.
↑Pisani, A; Gubellini, P; Bonsi, P; Conquet, F; Picconi, B; Centonze, D; Bernardi, G; Calabresi, P (2001). „Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-D-aspartate responses in medium spiny striatal neurons”. Neuroscience106 (3): 579–87. DOI:10.1016/S0306-4522(01)00297-4. PMID11591458.
↑Li, X; Need, AB; Baez, M; Witkin, JM (2006). „Metabotropic glutamate 5 receptor antagonism is associated with antidepressant-like effects in mice”. The Journal of Pharmacology and Experimental Therapeutics319 (1): 254–9. DOI:10.1124/jpet.106.103143. PMID16803860.
↑Kłodzińska, A; Tatarczyńska, E; Chojnacka-Wójcik, E; Pilc, A (2000). „Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats”. Polish journal of pharmacology52 (6): 463–6. PMID11334240.
↑Rasmussen, K; Martin, H; Berger, JE; Seager, MA (2005). „The mGlu5 receptor antagonists MPEP and MTEP attenuate behavioral signs of morphine withdrawal and morphine-withdrawal-induced activation of locus coeruleus neurons in rats”. Neuropharmacology48 (2): 173–80. DOI:10.1016/j.neuropharm.2004.09.010. PMID15695156.
↑Schröder, H; Wu, DF; Seifert, A; Rankovic, M; Schulz, S; Höllt, V; Koch, T (2009). „Allosteric modulation of metabotropic glutamate receptor 5 affects phosphorylation, internalization, and desensitization of the micro-opioid receptor”. Neuropharmacology56 (4): 768–78. DOI:10.1016/j.neuropharm.2008.12.010. PMID19162047.